Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Cytek Biosciences, Inc. reported year ended December 31, 2023 results: revenue $193.4 million, net income $11.3 million.
- Period
- year ended December 31, 2023
- Revenue
- $193.4 million
- Net income
- $11.3 million
- Result
- reported results
Exact text from the filing
the fourth quarter of 2022. Fourth quarter revenue from the product lines acquired from Luminex Corporation (“Luminex”) on February 28, 2023 was $9.8 million • Total revenue was $193.4 million, or $194.1 million on a non-GAAP constant currency basis, for the full year 2023, representing 18% and 13% increases, respectively, over the full year 2022. • Organic revenue was
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Cytek Biosciences, Inc. reported fourth quarter ended December 31, 2023 results: revenue $58.6 million, net income $6.3 million.
- Period
- fourth quarter ended December 31, 2023
- Revenue
- $58.6 million
- Net income
- $6.3 million
- Result
- reported results
Exact text from the filing
CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2023. Recent Highlights • Total revenue was $58.6 million, or $58.2 million on a non-GAAP constant currency basis, for the fourth quarter of 2023, representing 21% and 14% increases, respectively, over the corresponding period of 2022 •
View on SEC.gov